Abbott Launches Next-Generation Of EnSite Cardiac Mapping System
Executive Summary
The EnSite XP three-dimensional mapping earned a CE mark and regulatory approval in Australia.
You may also be interested in...
Cardio Conversations: Abbott's Electrophysiology CMO Christopher Piorkowski On Cardiac Mapping, PFA, VT And More
In this episode of Medtech Insight’s new podcast series focused on cardiovascular technology, editor Reed Miller talked to Christopher Piorkowski, Abbott's chief medical officer for electrophysiology.
US FDA Approves Abbott’s Sensor-Enabled TactiCath AF Catheter
The TactiCath - Sensor Enabled contact-force ablation catheter is indicated for cardiac electrophysiological mapping and the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation. It adds to Abbott EnSite Precision cardiac mapping system.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.